The global apheresis equipment market size was estimated at USD 3.43 billion in 2025 and is expected to reach USD 7.0 billion by 2033 at a CAGR of 9.4% from 2026 to 2033. The rising prevalence of blood-related disorders and favorable government initiatives, along with reimbursement frameworks, are expected to drive the market growth.
Furthermore, the rising popularity & participation in blood donation drives and camps, along with the growing number of blood transfusions, are anticipated to support the demand for apheresis equipment during the forecast period. Moreover, technological advancement and the development of portable apheresis devices are also likely to contribute to market growth.
Apheresis equipment plays a crucial role in treating leukemia, lymphoma, and myeloma, as these diseases often require blood component therapies. Patients with these conditions undergo apheresis for collecting specific blood components, such as platelets or white blood cells, for transfusion or therapeutic purposes. The high incidence of these diseases in the U.S., with approximately 184,720 new cases expected in 2023 alone, drives significant demand for apheresis equipment. In addition, autoimmune diseases and cancer are on the rise, further boosting the market growth. Approximately 4% of the world's population suffers from one of over 80 different autoimmune diseases, with therapeutic plasma exchange (TPE) widely used for treatment.
Moreover, the increasing number of platelet donors and research and development investments by biopharmaceutical companies are expected to bode well with the market. Apheresis, which allows the selective extraction of platelets while returning other blood components to the donor, is crucial for efficient platelet collection. In the U.S., there is a continuous demand for blood and platelets, with approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma needed daily. Sickle cell disease, affecting 90,000 to 100,000 people in the U.S., often requires lifelong blood transfusions, highlighting the critical role of apheresis equipment in providing these components. Factors such as increased awareness of platelet donation's impact on patient care and the growing reliance on platelet transfusions by healthcare facilities contribute to the rising number of platelet donors. Initiatives like the Health and Human Services' Giving = Living campaign, launched in August 2022, aim to raise awareness about the significance of blood and plasma donation and encourage Americans to establish regular donation routines. This campaign seeks to raise awareness about the significance of blood & plasma donation and motivate Americans to establish consistent donation routines.
In addition, technological advancements in apheresis are driving market growth by improving the efficiency, safety, and efficacy of procedures. Next-generation apheresis machines feature advanced software and hardware for enhanced process control, automation, and real-time monitoring, leading to more precise and reliable blood component collection. These machines offer personalized treatments for various patient needs and are designed for convenience and efficiency. In addition, advancements have led to the development of portable and user-friendly devices, expanding the use of apheresis beyond traditional hospital settings. Integration with Electronic Health Record systems has facilitated seamless data management and improved patient care. For example, Terumo BCT's Rika plasma collection system, cleared by the FDA in March 2022, enhances the donor and employee experience with safety features and faster collection times. These innovations demonstrate the industry's commitment to enhancing efficiency, quality, and donor safety in apheresis procedures.
The burgeoning field of regenerative medicine is experiencing a surge in demand for apheresis collection, with projections indicating a tripling of the annual collections in the U.S. from 43,000 in 2021 to an estimated 132,000 by 2025. This growth is largely driven by the expanding use of gene therapies and Chimeric Antigen Receptor (CAR) T-cell therapies, with the FDA currently approving two gene therapies for rare diseases and six CAR T-cell therapies for treating six distinct cancer types. The research pipeline is brimming with hundreds of cells and gene therapy products, many of which are in phase 3 trials, underscoring the need for apheresis services. The increased demand for apheresis has presented challenges for treatment centers, particularly in adapting to these new modalities. One key area of growth is the rise in photopheresis treatments for Graft-Versus-Host Disease (GVHD), which has been spurred by the growth of stem cell transplant programs, leading to a significant increase in apheresis procedures and necessitating the expansion of equipment and capacity.
Furthermore, the rising popularity & participation in blood donation drives and camps, along with the growing number of blood transfusions, are anticipated to support the demand for apheresis equipment during the forecast period. Moreover, technological advancement and the development of portable apheresis devices are also likely to contribute to market growth.
Apheresis equipment plays a crucial role in treating leukemia, lymphoma, and myeloma, as these diseases often require blood component therapies. Patients with these conditions undergo apheresis for collecting specific blood components, such as platelets or white blood cells, for transfusion or therapeutic purposes. The high incidence of these diseases in the U.S., with approximately 184,720 new cases expected in 2023 alone, drives significant demand for apheresis equipment. In addition, autoimmune diseases and cancer are on the rise, further boosting the market growth. Approximately 4% of the world's population suffers from one of over 80 different autoimmune diseases, with therapeutic plasma exchange (TPE) widely used for treatment.
Moreover, the increasing number of platelet donors and research and development investments by biopharmaceutical companies are expected to bode well with the market. Apheresis, which allows the selective extraction of platelets while returning other blood components to the donor, is crucial for efficient platelet collection. In the U.S., there is a continuous demand for blood and platelets, with approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma needed daily. Sickle cell disease, affecting 90,000 to 100,000 people in the U.S., often requires lifelong blood transfusions, highlighting the critical role of apheresis equipment in providing these components. Factors such as increased awareness of platelet donation's impact on patient care and the growing reliance on platelet transfusions by healthcare facilities contribute to the rising number of platelet donors. Initiatives like the Health and Human Services' Giving = Living campaign, launched in August 2022, aim to raise awareness about the significance of blood and plasma donation and encourage Americans to establish regular donation routines. This campaign seeks to raise awareness about the significance of blood & plasma donation and motivate Americans to establish consistent donation routines.
In addition, technological advancements in apheresis are driving market growth by improving the efficiency, safety, and efficacy of procedures. Next-generation apheresis machines feature advanced software and hardware for enhanced process control, automation, and real-time monitoring, leading to more precise and reliable blood component collection. These machines offer personalized treatments for various patient needs and are designed for convenience and efficiency. In addition, advancements have led to the development of portable and user-friendly devices, expanding the use of apheresis beyond traditional hospital settings. Integration with Electronic Health Record systems has facilitated seamless data management and improved patient care. For example, Terumo BCT's Rika plasma collection system, cleared by the FDA in March 2022, enhances the donor and employee experience with safety features and faster collection times. These innovations demonstrate the industry's commitment to enhancing efficiency, quality, and donor safety in apheresis procedures.
The burgeoning field of regenerative medicine is experiencing a surge in demand for apheresis collection, with projections indicating a tripling of the annual collections in the U.S. from 43,000 in 2021 to an estimated 132,000 by 2025. This growth is largely driven by the expanding use of gene therapies and Chimeric Antigen Receptor (CAR) T-cell therapies, with the FDA currently approving two gene therapies for rare diseases and six CAR T-cell therapies for treating six distinct cancer types. The research pipeline is brimming with hundreds of cells and gene therapy products, many of which are in phase 3 trials, underscoring the need for apheresis services. The increased demand for apheresis has presented challenges for treatment centers, particularly in adapting to these new modalities. One key area of growth is the rise in photopheresis treatments for Graft-Versus-Host Disease (GVHD), which has been spurred by the growth of stem cell transplant programs, leading to a significant increase in apheresis procedures and necessitating the expansion of equipment and capacity.
Global Apheresis Equipment Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global apheresis equipment market report based on product, application, procedure, technology, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Disposable Apheresis Kits
- Device
Application Outlook (Revenue, USD Million, 2021-2033)
- Renal Diseases
- Hematology
- Neurology
- Others
Procedure Outlook (Revenue, USD Million, 2021-2033)
- Plasmapheresis
- LDL apheresis
- Plateletpheresis
- Leukapheresis
- Photopheresis
- Erythrocytapheresis
- Others
Technology Outlook (Revenue, USD Million, 2021-2033)
- Membrane Filtration
- Centrifugation
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Apheresis Equipment Market Variables, Trends & Scope
Chapter 4. Apheresis Equipment Market: Product Estimates & Trend Analysis
Chapter 5. Apheresis Equipment Market: Procedure Estimates & Trend Analysis
Chapter 6. Apheresis Equipment Market: Application Estimates & Trend Analysis
Chapter 7. Apheresis Equipment Market: Technology Estimates & Trend Analysis
Chapter 8. Regional Estimates & Trend Analysis by Product, Application, Procedure, and Technology
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Apheresis Equipment market report include:- Asahi Kasei Medical Co., Ltd.
- Terumo BCT, Inc. (a Part of Terumo Corporation)
- Haemonetics Corporation
- Fresenius Kabi AG
- B. Braun SE
- Mallinckrodt plc
- Nikkiso Europe GmbH (a Part of NIKKISO Group)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | January 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 3.43 Billion |
| Forecasted Market Value ( USD | $ 7 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
